WASHINGTON — House lawmakers on both sides of the aisle Wednesday stressed the importance of developing new antibiotics, though the draft bill they discussed did not include any of the specific incentives advocates say are necessary to promote such drug development.

Left to their own devices and the stimuli of the market, companies simply won’t develop the antibiotics the world needs. Infections resistant to the current supply of medicines kill tens of thousands of Americans each year, and many more worldwide. But these drugs can’t turn a huge profit, and the more they are used, the less effective they can become, making it difficult for companies to recoup their investment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy